# E7438-G000-101 (NCT01897571)

> Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

No report yet. It can be ordered.

- Drugs tested: tazemetostat; tazemetostat plus prednisolone
- Indication: relapsed/refractory B-cell lymphomas and advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01897571
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Epizyme, Inc.
- Conditions: B-cell Lymphomas (Phase 1); Advanced Solid Tumors (Phase 1); Diffuse Large B-cell Lymphoma (Phase 2); Follicular Lymphoma (Phase 2); Transformed Follicular Lymphoma; Primary Mediastinal Large B-Cell Lymphoma
- Interventions: Tazemetostat; Prednisolone; Tazemetostat
- Enrollment: 400
- Primary outcome: Recommended Phase 2 Dose (RP2D) of Tazemetostat as a Single-Agent and in Combination With Prednisolone (Phase 1 Only)
- Primary outcome: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR]) (Phase 2)

## Indexed commentary on E7438-G000-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=e7438-g000-101-nct01897571